Resolvyx Pharmaceuticals

Recent Finacing

Series B

Recent Raise

$25M

Resolvyx is a biopharmaceutical company developing resolvins—endogenous small-molecule lipid mediators—with lead candidates RvE1 and RX-10045 and preclinical programs for asthma, atherosclerosis, IBD, dry eye, and retinal disease.

Founded 2001

Massachusetts, United States

11-50

Private

resolvyx.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Therapeutics

Recent Investors

B

Financials

$25M

Total Raised

1

Funding round

6

Investors